CA2418383A1 - Radiolabelled metal transport proteins as imaging agents - Google Patents
Radiolabelled metal transport proteins as imaging agents Download PDFInfo
- Publication number
- CA2418383A1 CA2418383A1 CA002418383A CA2418383A CA2418383A1 CA 2418383 A1 CA2418383 A1 CA 2418383A1 CA 002418383 A CA002418383 A CA 002418383A CA 2418383 A CA2418383 A CA 2418383A CA 2418383 A1 CA2418383 A1 CA 2418383A1
- Authority
- CA
- Canada
- Prior art keywords
- lactoferrin
- product according
- 99mtc
- tumour
- labelled
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229910052751 metal Inorganic materials 0.000 title claims abstract description 60
- 239000002184 metal Substances 0.000 title claims abstract description 60
- 102000014914 Carrier Proteins Human genes 0.000 title claims abstract description 47
- 108010078791 Carrier Proteins Proteins 0.000 title claims abstract description 47
- 239000012216 imaging agent Substances 0.000 title claims description 17
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 53
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 35
- 229910052742 iron Inorganic materials 0.000 claims abstract description 21
- 238000003384 imaging method Methods 0.000 claims abstract description 16
- 108010063045 Lactoferrin Proteins 0.000 claims description 37
- 229940078795 lactoferrin Drugs 0.000 claims description 36
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 35
- 235000021242 lactoferrin Nutrition 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 23
- 239000003638 chemical reducing agent Substances 0.000 claims description 22
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 7
- 239000007951 isotonicity adjuster Substances 0.000 claims description 7
- 238000002372 labelling Methods 0.000 claims description 7
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical group OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 claims description 6
- 239000012736 aqueous medium Substances 0.000 claims description 6
- 239000013011 aqueous formulation Substances 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 4
- 235000010323 ascorbic acid Nutrition 0.000 claims description 4
- 239000011668 ascorbic acid Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 238000011835 investigation Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- 229960005219 gentisic acid Drugs 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- IUTCEZPPWBHGIX-UHFFFAOYSA-N tin(2+) Chemical class [Sn+2] IUTCEZPPWBHGIX-UHFFFAOYSA-N 0.000 claims description 2
- 102100032241 Lactotransferrin Human genes 0.000 claims 18
- 239000003814 drug Substances 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 239000012581 transferrin Substances 0.000 description 44
- 102000004338 Transferrin Human genes 0.000 description 43
- 108090000901 Transferrin Proteins 0.000 description 43
- 239000000243 solution Substances 0.000 description 43
- 230000027455 binding Effects 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 21
- 229910052702 rhenium Inorganic materials 0.000 description 21
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 description 21
- 102000010445 Lactoferrin Human genes 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 15
- 238000001228 spectrum Methods 0.000 description 14
- 229910052713 technetium Inorganic materials 0.000 description 13
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 13
- 108010054176 apotransferrin Proteins 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 102000002070 Transferrins Human genes 0.000 description 7
- 108010015865 Transferrins Proteins 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 238000004448 titration Methods 0.000 description 7
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 108010038047 apolactoferrin Proteins 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000008033 biological extinction Effects 0.000 description 4
- 230000008499 blood brain barrier function Effects 0.000 description 4
- 210000001218 blood-brain barrier Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- 210000000172 cytosol Anatomy 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 108010083590 Apoproteins Proteins 0.000 description 2
- 102000006410 Apoproteins Human genes 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 108010026206 Conalbumin Proteins 0.000 description 2
- -1 Fe3+ ions Chemical class 0.000 description 2
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 2
- 101000766307 Gallus gallus Ovotransferrin Proteins 0.000 description 2
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 2
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 2
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000002059 diagnostic imaging Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 230000004992 fission Effects 0.000 description 2
- 229910052733 gallium Inorganic materials 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000003998 progesterone receptors Human genes 0.000 description 2
- 108090000468 progesterone receptors Proteins 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 235000011150 stannous chloride Nutrition 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 229910052779 Neodymium Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- JLJSYHOPCNWUNE-IEOVAKBOSA-N [99Tc].CC1=CC(C)=C(NC(=O)CN(CC(O)=O)CC(O)=O)C(C)=C1Br Chemical compound [99Tc].CC1=CC(C)=C(NC(=O)CN(CC(O)=O)CC(O)=O)C(C)=C1Br JLJSYHOPCNWUNE-IEOVAKBOSA-N 0.000 description 1
- DMVSPCYHPLCMJR-UHFFFAOYSA-N [Re].[Sc] Chemical compound [Re].[Sc] DMVSPCYHPLCMJR-UHFFFAOYSA-N 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 238000003705 background correction Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 239000012909 foetal bovine serum Substances 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- VCJMYUPGQJHHFU-UHFFFAOYSA-N iron(III) nitrate Inorganic materials [Fe+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O VCJMYUPGQJHHFU-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004890 malting Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- QEFYFXOXNSNQGX-UHFFFAOYSA-N neodymium atom Chemical compound [Nd] QEFYFXOXNSNQGX-UHFFFAOYSA-N 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 235000021048 nutrient requirements Nutrition 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- 230000002399 phagocytotic effect Effects 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 230000008866 synergistic binding Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000021510 thyroid gland disease Diseases 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000000954 titration curve Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-M tyrosinate group Chemical group N[C@@H](CC1=CC=C(C=C1)O)C(=O)[O-] OUYCCCASQSFEME-QMMMGPOBSA-M 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0019412.6A GB0019412D0 (en) | 2000-08-08 | 2000-08-08 | New imaging agent |
| GB0019412.6 | 2000-08-08 | ||
| PCT/GB2001/003531 WO2002011772A2 (en) | 2000-08-08 | 2001-08-07 | Radiolabelled metal transport proteins as imaging agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2418383A1 true CA2418383A1 (en) | 2002-02-14 |
Family
ID=9897174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002418383A Abandoned CA2418383A1 (en) | 2000-08-08 | 2001-08-07 | Radiolabelled metal transport proteins as imaging agents |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7160536B2 (enExample) |
| EP (1) | EP1307240A2 (enExample) |
| JP (1) | JP2004505932A (enExample) |
| AU (1) | AU2001278585A1 (enExample) |
| CA (1) | CA2418383A1 (enExample) |
| GB (1) | GB0019412D0 (enExample) |
| WO (1) | WO2002011772A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0019412D0 (en) * | 2000-08-08 | 2000-09-27 | Univ York | New imaging agent |
| JP2005517042A (ja) * | 2002-02-12 | 2005-06-09 | ヴィスタテック・ヨーク・リミテッド | 生体分子を放射性標識する方法 |
| WO2006047744A2 (en) | 2004-10-26 | 2006-05-04 | Agennix Incorporated | Compositions of lactoferrin related peptides and uses thereof |
| DE102005051366A1 (de) * | 2005-10-25 | 2007-04-26 | Degussa Gmbh | Drug Delivery Systeme |
| JP5264492B2 (ja) * | 2005-10-25 | 2013-08-14 | エボニック デグサ ゲーエムベーハー | 超分岐ポリマーを含有する調製物 |
| EP1982698A1 (de) * | 2007-04-18 | 2008-10-22 | Evonik Degussa GmbH | Präparate zur gesteuerten Freisetzung von bioaktiven Naturstoffen |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4057617A (en) | 1975-05-15 | 1977-11-08 | Abramovici J | Method of labeling proteins with technetium |
| FI950062A7 (fi) * | 1992-07-06 | 1995-01-05 | Biomira Inc | Proteiinien foroaktivaatio konjugaatiotarkoituksia varten |
| GB0019412D0 (en) * | 2000-08-08 | 2000-09-27 | Univ York | New imaging agent |
-
2000
- 2000-08-08 GB GBGB0019412.6A patent/GB0019412D0/en not_active Ceased
-
2001
- 2001-08-07 EP EP01956661A patent/EP1307240A2/en not_active Withdrawn
- 2001-08-07 JP JP2002517105A patent/JP2004505932A/ja active Pending
- 2001-08-07 WO PCT/GB2001/003531 patent/WO2002011772A2/en not_active Ceased
- 2001-08-07 CA CA002418383A patent/CA2418383A1/en not_active Abandoned
- 2001-08-07 AU AU2001278585A patent/AU2001278585A1/en not_active Abandoned
- 2001-08-07 US US10/344,079 patent/US7160536B2/en not_active Expired - Fee Related
-
2006
- 2006-10-05 US US11/543,671 patent/US20070036720A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004505932A (ja) | 2004-02-26 |
| US20070036720A1 (en) | 2007-02-15 |
| EP1307240A2 (en) | 2003-05-07 |
| WO2002011772A2 (en) | 2002-02-14 |
| WO2002011772A3 (en) | 2002-04-25 |
| GB0019412D0 (en) | 2000-09-27 |
| US20040013675A1 (en) | 2004-01-22 |
| US7160536B2 (en) | 2007-01-09 |
| AU2001278585A1 (en) | 2002-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sarko et al. | Bifunctional chelators in the design and application of radiopharmaceuticals for oncological diseases | |
| Rao et al. | Technetium (V) and rhenium (V) complexes of 2, 3-bis (mercaptoacetamido) propanoate. Chelate ring stereochemistry and influence on chemical and biological properties | |
| Maecke et al. | 68Ga-PET radiopharmacy: a generator-based alternative to 18F-radiopharmacy | |
| Sun et al. | Production and applications of copper-64 radiopharmaceuticals | |
| JPH05508699A (ja) | テクネチウムまたはレニウムでの抗体または他のタンパク質の直接放射能標識 | |
| JPS62270600A (ja) | キヤリヤ−分子の金属イオン標識化 | |
| JPH02504387A (ja) | 金属イオンで抗体を標識付けする方法 | |
| CZ20032597A3 (cs) | Analogy kyseliny askorbové pro metaloradiofarmaceutika | |
| KR20050119205A (ko) | 갈륨-68을 얻는 방법, 갈륨-68의 용도 및 상기 방법의수행을 위한 장치 | |
| EP0600992A1 (en) | Use of gentisic acid or gentisyl alcohol for stabilising radiolabeled peptides and proteins | |
| Liu et al. | Labeling biomolecules with radiorhenium-A review of the bifunctional chelators | |
| JPH07110869B2 (ja) | 放射性医薬品として使用できる９９ｍＴｃ、１８６Ｒｅまたは１８８Ｒｅの窒化物錯体の製造方法 | |
| JP7744240B2 (ja) | キレート化ａａｚｔａコンジュゲートおよびその錯体 | |
| JPS58126817A (ja) | 放射性核種標識タンパク質、とくに抗体または抗体断片の製造法 | |
| EP0719790B1 (en) | Metal chelate forming peptides and use thereof | |
| Frindel et al. | Cyclam te1pa for 64Cu PET imaging. Bioconjugation to antibody, radiolabeling and preclinical application in xenografted colorectal cancer | |
| JPH06508357A (ja) | 標識ポリペプチド、その製造法および使用 | |
| Ruser et al. | Synthesis and evaluation of two new bifunctional carboxymethylated tetraazamacrocyclic chelating agents for protein labeling with indium-111 | |
| US7160536B2 (en) | Radiolabelled metal transport proteins as imaging agents | |
| EP3452436A2 (en) | In-kit preparation of gallium-68 labelled radiopharmaceuticals | |
| Huynh et al. | Direct radiofluorination of a heat-sensitive antibody by Al–18F complexation | |
| Verbeke et al. | Technetium-99m mercaptoalbumin as a potential substitute for technetium-99m labelled red blood cells | |
| US5827498A (en) | Tumor affinity peptide, and radioactive diagnostic agent and radioactive therapeutic agent containing the peptide | |
| Kowalsky | Technetium radiopharmaceutical chemistry | |
| Bubenshchikov et al. | The impact of zirconium‐89 solution formulation on the efficiency of [89Zr] Zr‐deferoxamine synthesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |